AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 12 min read$TLRY

Tilray Just Posted Record Quarterly Revenue of $257 Million. So Why Did Its Cannabis Sales Shrink?

Tilray Brands reported record Q1 2027 revenue of $257.1M, up 23% YoY, with gross profit rising 35% to $77.5M. However, cannabis revenue fell 13% to $56.1M, driven by declines in Canadian sales. Beverage revenue surged 82% to $101.5M, now 39% of total revenue. Despite improvements, Tilray posted a $40M net loss and negative free cash flow.

Original reporting
finance.yahoo.com
Published Nov 1, 2026, 7:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 1, 2026, 8:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tilray Just Posted Record Quarterly Revenue of $257 Million. So Why Did Its Cannabis Sales Shrink? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TLRYBearishLow
01

Why it matters

The recap reinforces existing market perception of mixed performance, with negative earnings pressure.

02

Market read

Earnings recap with modest novelty; limited actionable insight.

03

What to watch

Strong cash position and debt reduction may provide runway for strategic pivots.

Relevance 4/10Novelty 2/10Timing: none

Background

Tilray's Q1 2027 earnings were released on 2026-10-08; this article recaps those results.

Company-level read

Ticker impact

$TLRYBearishMedium confidence
Context

Tilray Brands reported record Q1 revenue but a net loss of $40M and declining cannabis sales, reaffirming guidance.

Expected impact

likely pressure as investors weigh loss and cannabis decline against revenue growth

Evidence & confidence

The loss and negative free cash flow dominate the narrative, outweighing the revenue record.

Market effects

Sector

Highlights ongoing weakness in the Canadian cannabis market, may pressure peers.

Regional

Canada cannabis segment shows decline, could affect regional investors.

Global

Limited; primarily relevant to cannabis and beverage sectors.

Counterpoint

What could challenge this read

Revenue diversification into beverages could eventually offset cannabis weakness.

Key entities

  • company
    Tilray Brands

    US-listed cannabis and beverage company (NASDAQ: TLRY).

Read at source← All news

Related articles

OCT 29
$TLRYMed

Jefferies raises Tilray stock price target on brewing restructuring

Jefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.

investing.com2 min
OCT 13
$TLRYMed

Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility

Tilray Brands (TLRY) received approval from Portugal's INFARMED for in-house quality testing at its Cantanhede facility. This allows microbiological and chemical/physical testing on-site, improving control and speeding up product release. The company expects reduced costs and faster supply to key markets like Germany and the UK. TLRY's stock closed at $3.36, down 5.08%, and was down 0.30% in premarket trading.

rttnews.com2 min
OCT 13
$TLRYMed

Tilray Brands, Inc.: Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets

Tilray Medical, a division of Tilray Brands (TLRY), received approval from Portugal's INFARMED to conduct in-house quality testing at its Cantanhede facility. This allows for faster product release and strengthens its global medical cannabis supply chain, benefiting markets like Germany and the UK. The move is expected to reduce costs and improve efficiency, supporting Tilray's position as a leading medical cannabis supplier.

finanznachrichten.de2 min
OCT 9
$TLRYLow

Should you sell your Tilray stock?

Tilray Brands (TSX:TLRY) reported fiscal Q1 2027 revenue of $257.1M and Adjusted EBITDA of $9.2M, missing analyst estimates. Cannabis revenue fell 13% year-over-year, while beverage alcohol revenue rose 82.1%. Analyst Neal Gilmer maintained a 'Hold' rating and $4.00 target, citing concerns about organic growth and cash flow.

cantechletter.com2 min